Molybdenum-99 Market Size, Share, and Growth Forecast 2026 - 2033

The global Molybdenum-99 market is expected to be valued at US$ 963.7 million in 2026 and is projected to reach US$ 1,217.8 million by 2033, growing at a CAGR of 3.4% between 2026 and 2033.

Rising diagnostic imaging volumes and the shift toward secure, non-uranium supply chains are supporting market expansion. Molybdenum-99 (Mo-99) is the parent isotope of Technetium-99m (Tc-99m), which the OECD Nuclear Energy Agency (NEA) and the International Atomic Energy Agency (IAEA) estimate is used in roughly 80% of nuclear medicine diagnostic procedures, equivalent to about 40 million scans annually.

In the U.S., the National Nuclear Security Administration (NNSA) reports that Tc-99m supports more than 40,000 medical procedures each day. The growing burden of cardiovascular disease and cancer, combined with population aging, continues to support demand for single-photon emission computed tomography (SPECT) scans. At the same time, government-backed programs to replace aging research reactors, convert production from highly enriched uranium (HEU) to low-enriched uranium (LEU), and commercialize accelerator-based production routes are expanding and diversifying supply capacity.

Drivers - Rising Burden of Cardiovascular Disease and Cancer Elevates Tc-99m Diagnostic Volumes

The increasing prevalence of chronic diseases remains a major driver boosting the demand for Molybdenum-99. The World Health Organization (WHO) estimates that cardiovascular diseases cause around 17.9 million deaths annually, making them the leading cause of death globally, while the International Agency for Research on Cancer (IARC) recorded about 20 million new cancer cases in 2022 and projects this figure to exceed 35 million by 2050.

Tc-99m radiopharmaceuticals such as sestamibi and tetrofosmin are widely used in myocardial perfusion imaging, while Tc-99m methylene diphosphonate (MDP) is commonly used to detect skeletal metastases. Because Tc-99m has a half-life of about 6 hours and Mo-99 about 66 hours, neither isotope can be stockpiled for extended periods, creating a continuous supply requirement linked to diagnostic procedures. This relationship between diagnostic volumes and isotope consumption provides a recurring demand base for Mo-99 producers and generator manufacturers across major markets.

Government Programs Strengthen Supply Security and LEU Conversion

Public policy initiatives are reshaping and strengthening the Molybdenum-99 supply base. Following the 2009-2010 global shortage, when simultaneous outages of Canada's NRU reactor and the Netherlands' High Flux Reactor (HFR) disrupted supply, the NEA established the High-Level Group on the Security of Supply of Medical Radioisotopes (HLG-MR) to promote full-cost recovery and reserve capacity for reactor outages.

In the U.S., the American Medical Isotopes Production Act of 2012 directed the U.S. Department of Energy to support domestic, non-HEU Mo-99 production, while the NNSA has funded multiple commercial partners through cost-shared cooperative agreements. In Europe, the European Commission launched the SAMIRA action plan in 2021 under Europe's Beating Cancer Plan to strengthen medical radioisotope supply. These initiatives are encouraging investment in new production capacity, improving supply resilience, and increasing long-term market visibility for producers.

Restraints - Dependence on a Small Fleet of Aging Research Reactors

Global Molybdenum-99 supply remains concentrated among a limited number of research reactors, several of which have operated for more than half a century. Belgium's BR2 and the Netherlands' HFR began operation in 1961, South Africa's SAFARI-1 in 1965, and the Czech LVR-15 in 1957. Planned maintenance, unplanned shutdowns, and reactor repairs at these facilities have repeatedly contributed to supply interruptions, including extended HFR outages that disrupted the availability of diagnostic procedures. Because Mo-99 decays by roughly one percent every hour, producers have limited ability to build inventories that can offset prolonged supply gaps. This supply volatility increases procurement complexity for radiopharmacies, raises operating costs, and can reduce procedure volumes during shortages, limiting market growth relative to underlying clinical demand.

High Capital Costs, Regulatory Complexity, and Transport Constraints

Establishing new Molybdenum-99 production capacity requires substantial capital investment, lengthy licensing processes, and specialized nuclear infrastructure. Replacement reactors such as the Netherlands' PALLAS reactor and France's Jules Horowitz Reactor involve multi-year construction timelines and budgets reaching billions of euros. The NEA has also highlighted the historical underpricing of Mo-99 relative to its full production cost, which weakened the commercial case for new capacity until broader adoption of full-cost recovery mechanisms.

Strict radioactive material licensing requirements enforced by authorities such as the U.S. Nuclear Regulatory Commission (NRC) can further extend project timelines, while the IAEA has documented persistent shipment restrictions by airlines and ports for radioactive cargo. These factors increase operating costs, delay commercialization of new technologies, and constrain supply expansion into emerging markets.

Opportunities - Commercialization of Accelerator-Based and Non-Uranium Production Technologies

Accelerator-based production represents a significant opportunity for market participants seeking to reduce dependence on uranium targets and aging reactors. Technologies include fusion-driven neutron sources, such as those developed by SHINE Technologies in Janesville, Wisconsin, and electron linear accelerators that produce Mo-99 through photonuclear reactions using enriched Molybdenum-100 targets. In Canada, a TRIUMF-led consortium has also demonstrated direct cyclotron production of Tc-99m, supported by more than CAD 60 million in federal funding under the Isotope Technology Acceleration Program.

These technologies generate limited long-lived fissile waste, reduce proliferation concerns associated with HEU, and offer potential for production closer to end users, shortening delivery times. As regulatory frameworks develop and the NNSA continues supporting non-HEU domestic production, accelerator-based routes are anticipated to register the fastest growth among production methods through 2033, creating opportunities across technology licensing, strategic partnerships, and regional manufacturing.

Expanding Nuclear Medicine Infrastructure in Asia Pacific and Emerging Economies

Rapidly developing healthcare systems across Asia Pacific offer immense opportunities for Molybdenum-99 and Tc-99m demand. China's Medium and Long-term Development Plan for Medical Isotopes (2021-2035), issued by the China Atomic Energy Authority (CAEA) and partner agencies, targets stable domestic Mo-99 supply and broader access to nuclear medicine, including the goal of establishing at least one nuclear medicine department in every tertiary hospital. India's Board of Radiation and Isotope Technology (BRIT) continues to expand radiopharmaceutical distribution, while Southeast Asian countries are strengthening cancer screening and diagnostic infrastructure.

Meanwhile, the United Nations projects that the proportion of people aged 65 and above is projected to rise from about 10% in 2022 to 16% by 2050, with Asia accounting for the largest absolute increase. Producers establishing regional supply agreements, local generator assembly, and technical training partnerships with hospitals are positioned to capture rising demand as nuclear medicine infrastructure expands across emerging markets.

Production Method Insights

The fission segment is projected to lead the market by holding around 39% share in 2026. Fission-based production, in which uranium-235 targets are irradiated in research reactors and Mo-99 is chemically separated, yields high specific activity Mo-99 that is fully compatible with the column-based Tc-99m generators installed in hospitals and radiopharmacies worldwide. The segment benefits from decades of regulatory approval and established processing capacity operated by leading suppliers such as Curium, Institut National des Radioéléments (IRE), NTP Radioisotopes, and ANSTO.

The NEA notes that global conversion from HEU to LEU targets has been largely completed, strengthening the long-term regulatory acceptance of fission-based supply. ANSTO's ANSTO Nuclear Medicine (ANM) facility, commissioned in 2019, was designed to supply a substantial portion of global demand, further supporting the continued leadership of fission-based production.

Accelerator-based production is anticipated to be the fastest-growing production method through 2033, driven by growing investment in non-uranium isotope production technologies, government support for domestic medical isotope supply, and efforts to reduce dependence on aging research reactors. Fusion-neutron sources and electron accelerators offer alternative production pathways that can support more diversified and geographically distributed Mo-99 supply. Increasing development of photonuclear production using enriched Molybdenum-100 targets and direct cyclotron-based Tc-99m production is further strengthening interest in accelerator technologies.

Application Insights

Cardiovascular imaging is the leading application segment, accounting for around 34% of market share in 2026. Myocardial perfusion imaging (MPI) using Tc-99m sestamibi and Tc-99m tetrofosmin remains one of the most frequently performed nuclear medicine examinations, and cardiac studies are widely estimated to represent close to half of all Tc-99m procedures in the United States. The Centers for Disease Control and Prevention (CDC) reports that heart disease remains the leading cause of death in the U.S., with one person dying of cardiovascular disease around every 33 seconds. Clinical guidelines from the American Society of Nuclear Cardiology (ASNC) and the European Society of Cardiology (ESC) continue to recommend SPECT MPI for risk stratification in suspected coronary artery disease.

Oncology imaging is anticipated to be the fastest-growing application, driven by rising cancer incidence, increasing use of nuclear imaging for cancer staging, and expanding adoption of sentinel lymph node mapping. Tc-99m-based imaging agents support the identification of lymphatic spread and assist treatment planning across several cancer types. Growing oncology diagnostic volumes and expansion of nuclear medicine capabilities in emerging markets are further supporting demand for Mo-99-based Tc-99m supply.

End-User Insights

Hospitals are projected to hold a leading position in the market, accounting for around 57% share in 2026. Large hospitals operate a substantial proportion of nuclear medicine departments, SPECT and SPECT/CT systems, and hot labs capable of eluting Tc-99m from Mo-99 generators and preparing radiopharmaceuticals on site. Hospitals also manage high volumes of cardiac evaluations, oncology staging, and bone imaging, creating consistent requirements for Tc-99m-based diagnostic agents.

The IAEA Nuclear Medicine Database (NUMDAB) indicates that a large proportion of nuclear medicine units worldwide are hospital-based, particularly in emerging economies where standalone imaging centers remain less prevalent. The concentration of nuclear medicine infrastructure within hospitals therefore supports their leading share of Mo-99 demand.

Diagnostic imaging centers are anticipated to record the fastest growth through 2033, driven by the migration of routine cardiac and bone imaging toward outpatient settings, increasing availability of ambulatory diagnostic services, and centralized radiopharmacy delivery models. These facilities can access Tc-99m-based radiopharmaceuticals through external radiopharmacies, reducing the need for extensive on-site isotope processing infrastructure. Expansion of outpatient healthcare networks and growing demand for faster, lower-cost diagnostic services are further supporting the adoption of nuclear imaging across specialized diagnostic centers.

North America Molybdenum-99 Market Trends and Insights

North America is expected to lead the global Molybdenum-99 market with around 38% share in 2026, supported by the world's highest per-capita use of Tc-99m imaging and a mature network of centralized radiopharmacies. The region consumed around half of global Mo-99 supply but relied almost entirely on imports after Canada's NRU reactor ceased routine isotope production in 2016 and was permanently shut down in 2018. This dependence has triggered one of the world's most active supply diversification efforts, with federal agencies supporting domestic non-HEU production through fission, accelerator-based, and neutron activation routes.

Strong reimbursement frameworks, widespread SPECT/CT installations, and established cardiology imaging practices sustain consistent procedure volumes. A key regional trend is the emergence of vertically integrated domestic suppliers seeking to combine isotope production with generator manufacturing, improving supply resilience and reducing exposure to transatlantic shipping disruptions and overseas reactor outages.

U.S. Molybdenum-99 Market Size

The U.S. accounts for around 90% of the North American market revenue. Demand is anchored by more than 40,000 daily Tc-99m procedures reported by the NNSA, with the majority involving cardiac and bone scans. Since enactment of the American Medical Isotopes Production Act of 2012, the Department of Energy has supported several domestic producers, including SHINE Technologies and Northwest Medical Isotopes (NWMI), to build non-HEU capacity.

The University of Missouri Research Reactor (MURR) has also become an important partner for domestic irradiation services. Market opportunities are strengthened by broad Centers for Medicare & Medicaid Services (CMS) reimbursement for nuclear cardiology, a large aging population, and the growing clinical role of SPECT/CT hybrid imaging in oncology staging, which together sustain stable growth through 2033.

Europe Molybdenum-99 Market Trends and Insights

Europe is both a major consumer and the world's most important production hub for Molybdenum-99. Research reactors including BR2 in Belgium, HFR in the Netherlands, Maria in Poland, and LVR-15 in the Czech Republic irradiate a large share of global targets, which are processed by Curium in Petten and IRE in Fleurus. The Euratom Supply Agency (ESA), through its European Observatory on the Supply of Medical Radioisotopes, coordinates reactor schedules to minimize concurrent outages.

A defining regional trend is the multi-billion-euro investment in reactor replacement, notably PALLAS in the Netherlands and the Jules Horowitz Reactor in France, alongside Germany's planned Mo-99 production at the FRM II research reactor in Garching. The SAMIRA action plan further supports supply security, quality, and safety of medical radiation applications. Rising cancer screening, an aging population, and broad universal health coverage sustain steady procedure volumes across the region.

Germany Molybdenum-99 Market Size

Germany is the largest market within Europe, capturing an estimated 23% of the regional market revenue. The country hosts one of Europe's densest nuclear medicine networks, supported by the German Society of Nuclear Medicine (DGN) and statutory health insurance coverage for SPECT procedures. According to Destatis, cardiovascular disease remains the leading cause of death in Germany, accounting for roughly one-third of all fatalities, which drives sustained demand for myocardial perfusion imaging.

Future supply opportunities are linked to the Technical University of Munich's plans to establish Mo-99 production at the FRM II reactor, which has been designed with capacity to meet a substantial share of European demand once operational. Germany's aging demographic, with more than 22% of residents aged 65 and above, is expected to support stable volumes through 2033.

U.K. Molybdenum-99 Market Size

The U.K. is expected to hold around 15% share of the European market in 2026. The country has no domestic Mo-99 production reactor and relies entirely on imports from continental Europe, South Africa, and Australia, making it highly sensitive to reactor outages and cross-border transport disruptions. The National Health Service (NHS) performs a substantial number of nuclear medicine procedures every year, led by bone scans, cardiac imaging, and renal studies. Concerns over supply security have prompted government-commissioned reviews and support from bodies such as the UK National Nuclear Laboratory (NNL), which has explored options for domestic medical isotope production.

Growth opportunities stem from the NHS Long Term Plan's commitment to earlier cancer diagnosis, investment in community diagnostic centers, and increasing adoption of SPECT/CT systems across NHS trusts, which together are expected to support consistent demand through the forecast period.

France Molybdenum-99 Market Size

France is projected to hold about 18% of the European market share in 2026. The country is home to Curium, one of the world's largest producers of Mo-99 and Tc-99m generators, and to Framatome, which has expanded its isotope production activities. The French Alternative Energies and Atomic Energy Commission (CEA) is constructing the Jules Horowitz Reactor at Cadarache, which is designed to supply a significant share of European Mo-99 demand once operational, replacing capacity lost after the OSIRIS reactor closed in 2015.

France's extensive network of nuclear medicine departments, overseen by the French Nuclear Safety Authority (ASN), benefits from universal coverage through the national health insurance system. Growth opportunities are supported by national cancer strategies coordinated by the Institut National du Cancer (INCa) and rising demand for cardiac and oncology imaging among an aging population.

Asia Pacific Molybdenum-99 Market Trends and Insights

Asia Pacific is expected to be the fastest-growing market, driven by rapid expansion of nuclear medicine infrastructure, rising healthcare expenditure, and national policies aimed at isotope self-sufficiency. China represents the region's most dynamic market, with the China Atomic Energy Authority (CAEA) leading the Medium- and Long-term Development Plan for Medical Isotopes (2021-2035), which targets stable domestic Mo-99 supply and broader nuclear medicine access across tertiary hospitals.

China National Nuclear Corporation (CNNC) has been developing domestic production capacity to reduce reliance on imports. Australia contributes significant regional and export supply through ANSTO's OPAL reactor and the ANSTO Nuclear Medicine facility. Key regional trends include growing SPECT/CT installations, rising cancer and cardiovascular disease incidence, and the rapid aging of populations in East Asia. Regional producers are also investing in neutron activation and gel-generator technologies to expand local supply.

India Molybdenum-99 Market Size

India is projected to hold nearly 9% share of the Asia Pacific market in 2026, with strong growth potential. The Board of Radiation and Isotope Technology (BRIT), a unit of the Department of Atomic Energy (DAE), is the principal domestic supplier of Tc-99m generators and radiopharmaceutical kits, drawing on isotopes from Bhabha Atomic Research Centre (BARC) reactors, including Dhruva. Regulatory oversight by the Atomic Energy Regulatory Board (AERB) governs a growing network of several hundred nuclear medicine facilities.

The Indian Council of Medical Research (ICMR) estimates that cancer cases in India exceed 1.4 million annually, increasing demand for bone and oncology scans. Opportunities arise from the expansion of public health insurance under Ayushman Bharat, the development of new private cancer hospitals, and domestic gel-generator technologies based on neutron activation, which support decentralized supply.

Japan Molybdenum-99 Market Size

Japan is anticipated to hold around 38% share of the Asia Pacific market in 2026. The country is among the world's largest consumers of Tc-99m, yet historically imported virtually all of its Mo-99, leaving it exposed to overseas reactor outages and flight disruptions. To address this vulnerability, the Japan Atomic Energy Agency (JAEA) restarted the JRR-3 research reactor in 2021 and has pursued domestic Mo-99 production using neutron activation.

The Japan Radioisotope Association (JRIA) coordinates isotope distribution to hospitals nationwide. Demand is reinforced by the world's oldest population, with about 29% of citizens aged 65 or older according to the Statistics Bureau of Japan, and high rates of cardiac and cancer diagnostics under universal health insurance. Domestic production initiatives offer long-term opportunities for improved supply stability.

Southeast Asia Molybdenum-99 Market Size

Southeast Asia is expected to hold roughly 8% of the Asia Pacific market share in 2026. Indonesia's National Research and Innovation Agency (BRIN) operates the G.A. Siwabessy multipurpose reactor, which has historically supported regional radioisotope production, while Malaysia's Nuclear Malaysia, Thailand's Thailand Institute of Nuclear Technology (TINT), and Vietnam's Dalat Nuclear Research Institute contribute to local isotope and radiopharmaceutical capabilities.

The IAEA has supported numerous technical cooperation projects across the region to strengthen nuclear medicine services and workforce training. Growth is driven by rising cardiovascular and cancer incidence, expanding universal health coverage programs in Thailand, Indonesia, and Vietnam, and increasing private hospital investment in SPECT/CT systems. Opportunities exist for suppliers offering reliable generator logistics, regional distribution hubs, and training partnerships with hospitals.

The global Molybdenum-99 market is highly consolidated, with a limited number of irradiators and processors, notably Curium, IRE, NTP Radioisotopes, and ANSTO, supplying the majority of world demand. High barriers to entry, including reactor access, nuclear licensing, target fabrication, and hot-cell processing capabilities, reinforce this concentration. Market leaders differentiate through vertically integrated operations that span target irradiation, Mo-99 separation, generator manufacturing, and global distribution, alongside long-term supply contracts with multiple reactors to mitigate outage risk.

Research and development is focused on completing LEU conversion, improving processing yields, and qualifying new reactors such as PALLAS and Argentina's RA-10. Emerging entrants such as SHINE Technologies and Northwest Medical Isotopes are pursuing accelerator-based and domestic fission models. A notable business model trend is the pivot of isotope firms toward integrated diagnostic and therapeutic portfolios, using Mo-99 revenues to fund expansion into therapeutic radioisotopes.

Key Industry Developments

• In February 2024, NRG|PALLAS received a nuclear construction license from the Dutch Authority for Nuclear Safety and Radiation Protection (ANVS) for the PALLAS reactor in Petten, which is designed to replace the ageing HFR and secure long-term European Mo-99 supply.
• In 2023, NorthStar Medical Radioisotopes announced its exit from Mo-99 production and the RadioGenix System to concentrate resources on therapeutic radioisotopes, underscoring the commercial challenges facing new non-reactor Mo-99 entrants in the U.S. market.
• In 2024, SHINE Technologies continued advancing its fusion-based medical isotope production facility in Janesville, Wisconsin, positioning accelerator-driven neutron sources as a domestic, non-HEU source of Mo-99 for the U.S. market.